Benfotiamine and cognitive decline in Alzheimer’s disease: Results of a randomized placebo-controlled phase IIa clinical trial.

Manuscript Number: 

20-0896R1

Author(s): 
Lucien Bettendorff, Huanlian Chen, Zhengming Chen, Rosanna Cirio, Sarah Flowers, Pasquale Fonzetti, Jessica Franchino-Elder, Linda Gerber, Gary E. Gibson, Thomas Grandville, Christian Habeck, Joseph A. Hirsch, Barry Jordan, Jose A. Luchsinger, Nicole Schupf, Yaakov Stern, Hui Xu

Disclosures

Lucien Bettendorff

  • Nothing to Disclose

Zhengming Chen

  • Nothing to Disclose

Huanlian Chen

  • Nothing to Disclose

Rosanna Cirio

  • Nothing to Disclose

Sarah Flowers

  • Nothing to Disclose

Pasquale Fonzetti

  • Nothing to Disclose

Jessica Franchino-Elder

  • Nothing to Disclose

Linda Gerber

  • Nothing to Disclose

Gary E. Gibson

  • Nothing to Disclose

Thomas Grandville

  • Nothing to Disclose

Christian Habeck

  • Nothing to Disclose

Joseph A. Hirsch

  • Nothing to Disclose

Barry Jordan

  • Nothing to Disclose

Jose A. Luchsinger

  • Nothing to Disclose
    Patents/Royalties
    I

Nicole Schupf

  • Nothing to Disclose

Yaakov Stern

  • Consulting Fees:
    Consult for Eisai, Lilly, Arcadia
    Patents/Royalties
    Columbia University licenses the Dependence Scale, and in accordance with University policy, Dr. Stern is entitled to royalties through this license

Hui Xu

  • Nothing to Disclose